3,745 Shares in Zoetis Inc. (NYSE:ZTS) Bought by Minot DeBlois Advisors LLC

Minot DeBlois Advisors LLC acquired a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,745 shares of the company's stock, valued at approximately $610,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC increased its holdings in Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after buying an additional 140 shares during the period. Rakuten Securities Inc. increased its holdings in Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after buying an additional 166 shares during the period. Navigoe LLC acquired a new position in Zoetis in the 4th quarter worth approximately $30,000. Murphy & Mullick Capital Management Corp acquired a new position in Zoetis in the 4th quarter worth approximately $44,000. Finally, Asset Planning Inc acquired a new stake in shares of Zoetis during the 4th quarter worth approximately $58,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. The trade was a 2.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This represents a 9.71% decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Zoetis Trading Up 1.7%

ZTS traded up $2.68 on Friday, hitting $163.03. The company had a trading volume of 2,391,686 shares, compared to its average volume of 2,513,944. The firm has a market cap of $72.58 billion, a P/E ratio of 29.80, a PEG ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The company's fifty day moving average price is $156.49 and its 200 day moving average price is $165.56. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. During the same period in the previous year, the company posted $1.38 EPS. Zoetis's revenue was up 1.4% compared to the same quarter last year. As a group, equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Morgan Stanley dropped their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Stifel Nicolaus dropped their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. UBS Group dropped their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Finally, Barclays raised their price objective on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $212.75.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.